

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application Of:)	Group Art Unit: 1633
)	
Mark J. COOPER <i>et al.</i>)	Examiner: Scott Long
)	
Serial No.: 10/656,192)	
)	Docket No. 003659.00009
Filed: September 8, 2003)	
)	Confirmation No. 8424
)	

For: LYOPHILIZABLE AND ENHANCED COMPACTED NUCLEIC ACIDS

RESPONSE TO RESTRICTION REQUIREMENT
and AMENDMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Species Election Requirement mailed June 2, 2006, applicants elect for prosecution in this application

- cDNA as recited in claim 17; claims 1-16, 18-19, 21-22, and 24-62, 63-75, 76-82, 83-88, 90-96, and 97-123 are said to be generic in this respect.
- CK15-60P10 as recited in claims 51, 63, 76, 83, and 90; claims 1-50, 52-62, 64-75, 77-82, 84-89, 91-96, and 102-123 are said to be generic in this respect.
- Acetate as recited in claims 1, 8, 17, 20, 23, 26, 28, 51, 63, 77, 83, 90, and 97-101; claims 1-7, 9-16, 18-19, 21-22, 24-25, 30-50, 52-62, 63-75, 77-82, 84-89, 91-96, and 120-123 are said to be generic in this respect.

Claims indicated above as reciting or being generic to the elected species read on the elected species.